Margetuximab-cmkb

(Margenza®)

Margenza®

Drug updated on 5/17/2024

Dosage FormInjection (intravenous; 250 mg/10 mL [25 mg/mL])
Drug ClassHER2/neu receptor antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in combination with chemotherapy, for the treatment of adult patients with metastatic HER2- positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Margetuximab-cmkb (Margenza) is indicated in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
  • Two randomized controlled studies were reviewed to gather information about Margenza's safety and effectiveness compared to trastuzumab in treating this patient population.
  • The overall survival analysis did not show a significant advantage of Margenza over trastuzumab. However, a subgroup exploratory analysis showed potential improved overall survival for Margenza in patients with the CD16A-158FF genotype.
  • A significant improvement was observed in progression-free survival among patients receiving Margenza compared to those on trastuzumab. This indicates that despite similar overall survival rates, there may be benefits associated with using margetuximab-cmkb (Margenza).
  • Objective response rate also improved with the use of margetuximab-cmkb (Margenza), indicating a more favorable response regarding tumor reduction as opposed to its counterpart drug.
  • The safety profile between both medications appears comparable; however, it should be noted that there is a higher incidence of infusion-related reactions reported during initial administration cycles with margetuximab-cmkb (Margenza).

Product Monograph / Prescribing Information

Document TitleYearSource
Margenza (margetuximab-cmkb) Prescribing Information.2023MacroGenics, Inc., Rockville, MD

Randomized Controlled Trials

Clinical Practice Guidelines